In an editorial published in the Oct. 19 issue of the Journal of the American Medical Association, Peter V. Rabins, M.D., M.P.H., and Constantine G. Lyketsos, M.D., M.H.S., professors of psychiatry at The Johns Hopkins University School of Medicine, cautioned that clinicians should consider both the risks and benefits for patients suffering from dementia, such as Alzheimer's disease, and when possible delay prescribing so-called second-generation antipsychotic medications for patients who exhibit psychotic symptoms or aggression.

A study of the effects of these drugs, including aripiprazole, olanzapine, quetiapine and risperidone, in elderly patients with dementia, led by Lon S. Schneider, M.D., M.S., of the University of Southern California, Los Angeles, is featured in the same edition of JAMA.

The authors of that study reviewed all available published and unpublished randomized placebo-controlled, parallel-group, clinical trials of the second-generation antipsychotic drugs marketed in the United States to treat patients with dementia.

They concluded that the patients taking second-generation antipsychotic medications were 1.5 times more likely to die than patients taking a placebo.

"These results," said Rabins, "do not suggest that first-generation antipsychotic drugs like haloperidol and chlorpromazine, introduced in the 1950s, are safer alternatives to second-generation drugs."

He said first-generation antipsychotic drugs have their own set of adverse side effects, such as Parkinson's disease-like symptoms and low blood pressure.

"We do not believe the findings contraindicate the use of antipsychotics for patients with dementia who have psychotic symptoms and agitation, but rather that they change the risk-benefit analysis such that an
'"/>

Contact: Eric Vohr
evohr1@jhmi.edu
410-955-8665
Johns Hopkins Medical Institutions
18-Oct-2005